Release date: March 23, 2018
Expiration date: March 23, 2019
Estimated time to complete activity: 1.5 hours
This activity will run from March 2018 through March 2019. It will consist of highlights from SABCS 2017, and will include commentary from the faculty providing their perspectives on the presentations and discussions at the meeting. Topics of special interest will include:
- Existing and emerging targeted therapies
- Identification of new molecular targets for treating breast cancer
- Optimal use of hormone therapy
- The role of immune checkpoint inhibitors in treating advanced breast cancer
- Prognostic and predictive molecular biomarkers
- Integrating recent research developments into clinical practice
The monograph will also be hosted online on the following websites for 1 year, providing all potential learners with additional opportunities to learn and earn CE credit. The online monograph will also be available for 1.5 CME/CE credit hours: www.LynxCME.com.
This educational activity is directed toward medical and surgical oncologists, oncology nurses and nurse practitioners, and other healthcare professionals involved in the management of patients with breast cancer. Research scientists interested in the development of targeted agents for the personalized treatment of patients with breast cancer will also benefit from participating in this activity.
Upon completion of the educational activity, participants should be able to:
- Describe the latest advances in the management of patients with breast cancer
- Apply clinical data on targeted agents, immunotherapy, and combination therapies in treatment approaches for patients with advanced breast cancer
- Discuss the role of recently discovered molecular pathways in driving targeted therapy of breast cancer
- Incorporate recent data on molecular biomarkers into clinical practice in the management of patients with advanced breast cancer
|Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Cancer Research
||AstraZeneca, Celgene, Lilly, Novartis, Pfizer
|Sara Tolaney, MD, MPH
Senior Physician/Associate Director, Susan F. Smith Center for Women’s Cancers; Associate Director for Clinical Research in the Breast Oncology Center, Dana-Farber Cancer Institute; Director of Breast Immunotherapy Clinical Research, Assistant Professor of Medicine, Harvard Medical School, Boston, MA
|AstraZeneca, Lilly, Merck, Nanostring, Nektar, Novartis, Pfizer, Puma
AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Lilly, Merck, Nektar, Novartis, Pfizer
|Dorothy Caputo, MA, BSN, RN
CE Director of Accreditations
||Nothing to disclose
| Bernadette Marie Makar, MSN, NP-C, APRN-C-BC
||Nothing to disclose
|The COE Staff and Planners
||Nothing to disclose
|AKH Planners and Reviewers
||Nothing to disclose
Criteria for Success
In order to receive credit, participants should read the monograph. Once you have read the monograph, you will continue to the online quiz and evaluation. A passing score of 70% on the quiz is required to receive credit. A statement of credit will be available upon successful completion of the quiz and evaluation at: http://akhcme.com/akhcme/pages/lynx21853.
There is no fee for this activity.
If you have questions about this CME/CE activity, please contact AKH Inc. at: firstname.lastname@example.org.
CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Center of Excellence Media, LLC – An affiliate of The Lynx
Group. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity is awarded 1.5 Contact Hours.
This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Center of Excellence Media, LLC – An affiliate of The Lynx Group. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.
This activity is approved for 1.5 contact hour(s) which includes 1.0 hour(s) of pharmacology. Activity ID # 21853.
This activity is supported by an educational grant from Eisai.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or a combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment.
The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.